Categories
Biotech Healthcare Patents Pharma

[Archived Post] Professors Erika Lietzan and Kristina Acri Argue That Current Data Do Not Support Evergreening Allegations

By Jack Ring In their forthcoming paper, Solutions Still Searching for a Problem: A Call for Relevant Data to Support “Evergreening” Allegations,[1] C-IP2 Senior Scholars Erika Lietzan of Mizzou Law and Kristina Acri of Colorado College call for relevant data to support evergreening allegations and accompanying policy proposals. “Evergreening” is often described as brand drug […]

Categories
Pharma

[Archived Post] C-IP2 Statement on Interactions between Courts and the FDA

Courts have recently questioned Food and Drug Administration (FDA) determinations. The FDA is the administrative agency whose job is to evaluate scientific data to determine if a drug is safe and effective enough to be approved, and post-approval, to continue to evaluate such data to determine if a drug should remain available.   Generally, the most […]

Categories
Patents Pharma

[Archived Post] Policy Brief: The TRIPS Waiver for COVID-19 Vaccines, and Its Potential Expansion: Assessing the Impact on Global IP Protection and Public Health

This policy brief, including the following “Introduction and Executive Summary,” comes from Eric M. Solovy. CLICK HERE to read the brief in full. Introduction and Executive Summary On June 17, 2022, in the early morning hours of the final day of the World Trade Organization’s (“WTO”) 12th Ministerial Conference, the Members of the WTO adopted […]

Categories
Biotech Patents Pharma

[Archived Post] Reply and Response to C-IP2’s March 4, 2021, Blogpost on UC Hastings’ Evergreen Drug Patent Search Database

C-IP2’s original post on the UC Hastings’ Evergreen Drug Patent Search Database can be read here. Reply to Blog Post on UC Hastings’ Evergreen Drug Patent Search Database Robin Feldman Arthur J. Goldberg Distinguished Professor of Law Albert Abramson ’54 Distinguished Professor of Law Chair Director of the Center for Innovation at University of California […]

Categories
Biotech C-IP2 News International Law Patents

[Archived Post] Panel Discussion: Vaccines, Intellectual Property, and Global Equity

The following post comes from Colin Kreutzer, a 2E at Scalia Law and a Research Assistant at C-IP2.  The COVID-19 pandemic has shined a spotlight on the role of intellectual property in modern medicine and on the complex social questions surrounding a system that grants exclusive rights over life-or-death products. On the one hand, there […]

Categories
FTC Healthcare

[Archived Post] CPIP Scholars Join Comments to FTC on How Antitrust Overreach is Threatening Healthcare Innovation

On December 21, 2018, CPIP Senior Scholars Adam Mossoff and Kristen Osenga joined former Federal Circuit Chief Judge Randall Rader and SIU Law’s Mark Schultz in comments submitted to the FTC as part of its ongoing Competition and Consumer Protection in the 21st Century Hearings. Through the hearings, the FTC is examining whether recent economic […]

Categories
Innovation Pharma

[Archived Post] The Drug Innovation Paradox: Matching Incentives to Market Realities

The hardest things are often the most important things. That’s one of the implicit justifications for the intellectual property system. If we want people to do the hard and important work of researching, developing, and commercializing game-changing innovations, then we need to secure the fruits of their labor with property rights.In her forthcoming paper, The […]

Categories
Biotech Commercialization Conferences Copyright Innovation Intellectual Property Theory Inventors Uncategorized

[Archived Post] The Common Economic Case for Patents and Copyrights

This is the second in a series of posts summarizing CPIP’s 2014 Fall Conference, “Common Ground: How Intellectual Property Unites Creators and Innovators.” The Conference was held at George Mason University School of Law on October 9-10, 2014.  Videos of the conference panels and keynote will be available soon. The opening panel of CPIP’s 2014 […]